Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Kheiron Medical Technologies found in HSH's search of the last 24 months. Note: Kheiron was acquired by DeepHealth, a RadNet subsidiary, in Oct 2024.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Kheiron Medical Technologies found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No product recalls, safety notices or clinical safety actions involving Kheiron Medical Technologies or its Mia product found in HSH's search of the last 24 months. The UK National Screening Committee does not currently recommend AI for NHS breast screening.
Contract delivery, go-lives, terminations and disputes.
Mar 2026: A Nature Cancer evaluation of Kheiron's Mia in NHS Grampian breast screening (10,889 women) reported 10.4% more cancers detected; wider UK evaluation is planned through the EDITH trial.